BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 21807409)

  • 1. Accelerated healing of cutaneous leishmaniasis in non-healing BALB/c mice using water soluble amphotericin B-polymethacrylic acid.
    Corware K; Harris D; Teo I; Rogers M; Naresh K; Müller I; Shaunak S
    Biomaterials; 2011 Nov; 32(31):8029-39. PubMed ID: 21807409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biodistribution and
    Iman M; Huang Z; Alavizadeh SH; Szoka FC; Jaafari MR
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relation between Skin Pharmacokinetics and Efficacy in AmBisome Treatment of Murine Cutaneous Leishmaniasis.
    Wijnant GJ; Van Bocxlaer K; Yardley V; Harris A; Murdan S; Croft SL
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis.
    Jaafari MR; Hatamipour M; Alavizadeh SH; Abbasi A; Saberi Z; Rafati S; Taslimi Y; Mohammadi AM; Khamesipour A
    Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():156-165. PubMed ID: 31582344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis.
    Abu Ammar A; Nasereddin A; Ereqat S; Dan-Goor M; Jaffe CL; Zussman E; Abdeen Z
    Drug Deliv Transl Res; 2019 Feb; 9(1):76-84. PubMed ID: 30484256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome
    Wijnant GJ; Van Bocxlaer K; Yardley V; Harris A; Alavijeh M; Silva-Pedrosa R; Antunes S; Mauricio I; Murdan S; Croft SL
    Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):223-228. PubMed ID: 29673889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacious treatment of experimental leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives.
    Golenser J; Frankenburg S; Ehrenfreund T; Domb AJ
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2209-14. PubMed ID: 10471566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Designing of a Gel Formulation with Chitosan Polymer Using Liposomes as Nanocarriers of Amphotericin B for a Non-invasive Treatment Model of Cutaneous Leishmaniasis.
    Gürbüz Çolak N; Çetin Uyanikgil EÖ; Özbel Y; Töz S
    Acta Parasitol; 2022 Sep; 67(3):1354-1363. PubMed ID: 35857275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An amphotericin B-based drug for treating experimental Leishmania major infection.
    Corware KD; Rogers M; Teo I; Müller I; Shaunak S
    Trans R Soc Trop Med Hyg; 2010 Nov; 104(11):749-50. PubMed ID: 20850850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S-nitrosoglutathione (GSNO) is cytotoxic to intracellular amastigotes and promotes healing of topically treated Leishmania major or Leishmania braziliensis skin lesions.
    Costa IS; de Souza GF; de Oliveira MG; Abrahamsohn Ide A
    J Antimicrob Chemother; 2013 Nov; 68(11):2561-8. PubMed ID: 23788476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bovine serum albumin nanoparticles containing amphotericin B were effective in treating murine cutaneous leishmaniasis and reduced the drug toxicity.
    Casa DM; Scariot DB; Khalil NM; Nakamura CV; Mainardes RM
    Exp Parasitol; 2018 Sep; 192():12-18. PubMed ID: 30026113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
    Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
    Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of in vitro and in vivo Efficacy of a Novel Amphotericin B-Loaded Nanostructured Lipid Carrier in the Treatment of
    Rebouças-Silva J; Tadini MC; Devequi-Nunes D; Mansur AL; S Silveira-Mattos P; I de Oliveira C; R Formiga F; Berretta AA; Marquele-Oliveira F; Borges VM
    Int J Nanomedicine; 2020; 15():8659-8672. PubMed ID: 33177824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanodisk-associated amphotericin B clears Leishmania major cutaneous infection in susceptible BALB/c mice.
    Nelson KG; Bishop JV; Ryan RO; Titus R
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1238-44. PubMed ID: 16569834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microparticles.
    Sousa-Batista AJ; Pacienza-Lima W; Ré MI; Rossi-Bergmann B
    Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():148-155. PubMed ID: 31331828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea.
    Guery R; Henry B; Martin-Blondel G; Rouzaud C; Cordoliani F; Harms G; Gangneux JP; Foulet F; Bourrat E; Baccard M; Morizot G; Consigny PH; Berry A; Blum J; Lortholary O; Buffet P;
    PLoS Negl Trop Dis; 2017 Nov; 11(11):e0006094. PubMed ID: 29155816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A targeted and adjuvanted nanocarrier lowers the effective dose of liposomal amphotericin B and enhances adaptive immunity in murine cutaneous leishmaniasis.
    Daftarian PM; Stone GW; Kovalski L; Kumar M; Vosoughi A; Urbieta M; Blackwelder P; Dikici E; Serafini P; Duffort S; Boodoo R; Rodríguez-Cortés A; Lemmon V; Deo S; Alberola J; Perez VL; Daunert S; Ager AL
    J Infect Dis; 2013 Dec; 208(11):1914-22. PubMed ID: 23901083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of amiodarone in treatment of cutaneous leishmaniasis caused by Leishmania major.
    Bemani E; Oryan A; Bahrami S
    Exp Parasitol; 2019 Oct; 205():107747. PubMed ID: 31442454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis.
    Riezk A; Van Bocxlaer K; Yardley V; Murdan S; Croft SL
    Molecules; 2020 Sep; 25(17):. PubMed ID: 32887341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a di-stigma-steryl-hemi-succinoyl-glycero-phosphocholine liposome-intercalated amphotericin B.
    Iman M; Huang Z; Szoka FC; Jaafari MR
    Int J Pharm; 2011 Apr; 408(1-2):163-72. PubMed ID: 21277963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.